Biocompatibility Testing for Medical Devices: ISO 10993 Complete Guide

The ISO 10993 Framework: A Risk-Based Approach to Biocompatibility

ISO 10993 is an international standard series covering the biological evaluation of medical devices. The central standard, ISO 10993-1, was significantly revised in its 2018 version to explicitly frame biocompatibility evaluation as a risk management activity rather than a checklist of biological tests.

This is not a semantic distinction. Under ISO 10993-1:2018, the starting point for any biocompatibility evaluation is material characterization and chemical characterization — understanding what the device is made of at a detailed chemical level — not identifying which tests to run. If chemical characterization demonstrates that the device materials are established, well-characterized materials with known biocompatibility profiles, extensive biological testing may not be required. Conversely, novel materials, significant processing changes, or materials used in new contact applications may require a comprehensive biological testing program.

FDA updated its guidance on biocompatibility evaluation for medical devices in 2016 and has since issued additional guidance and FAQ documents that align with ISO 10993-1:2018's risk-based framework. FDA's current expectation is a Biological Evaluation Report (BER) that documents a systematic, risk-based analysis — not a list of completed tests with results.

For 510(k) submissions, PMA applications, and De Novo requests, FDA reviewers will examine the BER and assess whether the evaluation is methodologically sound and whether the conclusions are supported by the evidence. Submissions that provide test results without an integrated risk analysis are increasingly receiving Additional Information (AI) requests from FDA.

Device Contact Categories and Exposure Duration

ISO 10993-1 classifies devices by the nature of their body contact and the duration of that contact, because these two factors determine which biological endpoints are relevant.

Contact categories: Surface-contacting devices include those contacting intact skin (e.g., electrodes, external prostheses), mucosal membranes (e.g., oral devices, contact lenses), and breached or compromised skin (e.g., wound dressings). Externally communicating devices include those contacting blood path (indirect), tissue/bone/dentin, or circulating blood. Implant devices contact tissue/bone or blood.

Duration categories: Limited contact is less than 24 hours cumulative. Prolonged contact is 24 hours to 30 days. Permanent contact is more than 30 days.

The combination of contact category and duration drives the biological endpoints that must be evaluated. For example, a permanently implanted device contacting blood must be evaluated for cytotoxicity, sensitization, intracutaneous reactivity, systemic toxicity, subchronic toxicity, genotoxicity, implantation, hemocompatibility, and additional endpoints as appropriate. A limited-contact skin surface device has a substantially shorter list of required endpoints.

Using the ISO 10993-1 evaluation matrix: ISO 10993-1 Annex A provides the biological evaluation matrix — a table mapping contact category and duration to required and potentially required biological evaluation endpoints. The matrix is a starting point, not a complete decision guide. Your BER must justify which endpoints are addressed through testing, material characterization data, literature, or a conclusion that the endpoint is not applicable with reasoning.

Chemical Characterization: The Foundation of Modern Biocompatibility

ISO 10993-18:2020 covers chemical characterization of materials used in medical devices — the identification and quantification of chemical substances that could potentially be released from a device and come into contact with the body. Chemical characterization has become the cornerstone of modern biocompatibility evaluation because it enables risk-based decisions about whether biological testing is needed and at what level.

The chemical characterization process begins with material identification: documenting the chemical composition of all device materials, including base polymers, additives (plasticizers, stabilizers, colorants, flame retardants), processing aids, sterilization residuals, and packaging materials that contact the device.

Extractables and leachables: ISO 10993-18 distinguishes between extractables (chemicals that can be extracted from a material under exaggerated laboratory conditions) and leachables (chemicals that actually migrate from a device under clinical conditions). Extractables testing establishes a worst-case inventory of what chemicals are present in the material. Leachables characterization estimates what a patient is actually exposed to.

Toxicological risk assessment: ISO 10993-17:2023 covers the establishment of allowable limits for leachables. For each identified leachable, a toxicological risk assessment evaluates the available toxicological data (or applies read-across from structurally similar compounds) and determines a Tolerable Intake (TI) based on the chemical's toxicological profile. The TI is then compared to the estimated patient exposure to determine whether the exposure is within acceptable limits.

If chemical characterization and toxicological risk assessment demonstrate that all identified leachables are within acceptable limits, biological testing for systemic toxicity endpoints may not be required. This is a significant efficiency gain compared to running biological tests for every device regardless of material profile.

Biological Testing: When It Is Required and How to Plan It

When chemical characterization and toxicological risk assessment leave residual uncertainties — because data is insufficient, materials are novel, or the toxicological analysis identifies chemicals above their TI — biological testing is required to address those uncertainties.

Selecting a test laboratory: ISO 10993 biological tests must be conducted by laboratories with appropriate expertise, typically ISO 17025-accredited for the specific test methods. For FDA submissions, tests conducted by non-GLP (Good Laboratory Practice) laboratories may not be acceptable for in vivo biological tests. Confirm laboratory qualifications and GLP compliance before contracting.

ISO 10993 test standards by endpoint: - Cytotoxicity: ISO 10993-5 (cell culture assays) - Sensitization: ISO 10993-10 (guinea pig maximization or LLNA murine local lymph node assay) - Intracutaneous reactivity: ISO 10993-10 (rabbit model) - Systemic toxicity (acute): ISO 10993-11 (mouse or rat model) - Subacute/subchronic/chronic toxicity: ISO 10993-11 - Genotoxicity: ISO 10993-3 (battery of in vitro and in vivo tests) - Implantation: ISO 10993-6 (tissue response at implant site) - Hemocompatibility: ISO 10993-4 (hemolysis, thrombogenicity, complement activation)

Test article selection: The device or representative material used in biological testing must be clinically representative. For polymeric devices, test articles should be processed identically to production devices, including sterilization. Processing changes between development and production can invalidate biological test results if the processing materially changes the extractable profile.

ISO 10993-12: Sample preparation: The method of sample preparation (extraction conditions, extraction media, extraction ratio) significantly affects test results. ISO 10993-12 provides guidance on sample preparation that must be documented and justified in your BER.